Completed PHASE1 INTERVENTIONAL 5-arm NCT05944848

A Study of CL-197 Capsules in Healthy Participants

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of CL-197 Capsules Administered in Single Dose in Healthy Participants

Sponsor: Henan Genuine Biotech Co., Ltd.

Conditions HIV-1

Interventions 1 mg CL-197 capsules 10 mg CL-197 capsules or CL-197 placebo 100 mg CL-197 capsules or CL-197 placebo 30 mg CL-197 capsules or CL-197 placebo 60 mg CL-197 capsules or CL-197 placebo

Updated 5 times since 2023 Last updated: Apr 23, 2024 Started: Nov 16, 2022 Primary completion: Jan 20, 2024 Completion: Jan 20, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates HIV-1 and is currently completed. Henan Genuine Biotech Co., Ltd. leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

May 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — May 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2024 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Aug 2023 — May 2024 [monthly]

Recruiting PHASE1

First recorded

Nov 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henan Genuine Biotech Co., Ltd.

Data source: Henan Genuine Biotech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China